Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pembrolizumab
Find trials that include:  Any drugs shown
Results 1-25 of 158 for your search:
Start Over
Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20110265, NCI-2015-00094, 2014-000185-22, NCT02263508
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-054, NCI-2015-01366, 1325-MG, 2014-004944-37, NCT02362594
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-062, NCI-2015-01332, 163187, 2015-000972-88, NCT02494583
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients with Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1404, NCI-2014-02676, NCT02506153
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-183, NCI-2015-01850, 163146, 2015-002509-13, NCT02576977
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-185, NCI-2015-01851, 163239, 2015-002901-12, NCT02579863
Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-189, NCI-2015-02271, 2015-003694-15, NCT02578680
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHP-OCM-301, NCI-2016-00242, NCT02678572
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-119, NCI-2016-00327, 153082, 2015-001020-27, NCT02555657
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-204, NCI-2016-00839, 2015-005053-12, NCT02684292
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-301, NCI-2016-00978, NCT02752074
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Pembrolizumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1454GCC, NCI-2015-01784, GCC1454 / HP-00061522, HCR-HP-00061522-1, HP-00061522, NCT02289222
MK-3475 in Combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS142-03, NCI-2015-02095, NCT02325557
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 6 months to less than 18 years
Trial IDs: 3475-051, NCI-2015-00528, 2014-002950-38, NCT02332668
ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-LY-005, NCI-2015-01019, NCT02362035
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: HCRN GU14-188, NCI-2015-01257, NCT02365766
Start Over